Related Experiment Video

Updated: May 10, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.5K

Perioperative glycemic control in patients undergoing cardiac surgery

Dariusz Bednarski1, Łukasz J Krzych2,3

  • 1Department of Anesthesiology and Intensive Care, School of Medicine, Medical University of Silesia, Katowice, Poland.

Kardiochirurgia I Torakochirurgia Polska = Polish Journal of Cardio-Thoracic Surgery
|April 28, 2025
PubMed

Insights

Effective perioperative glycemic control is crucial for patients with diabetes mellitus undergoing cardiac surgery. Proper blood sugar management significantly reduces postoperative mortality and complications, improving patient outcomes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Anesthesiology

Background:

  • Diabetes mellitus affects over 537 million adults globally, with cardiovascular disease as a leading cause of mortality.
  • Approximately 40% of diabetes patients require cardiac surgery, primarily coronary artery procedures.
  • Uncontrolled hyperglycemia is a major independent risk factor for postoperative mortality and severe complications in these patients.

Purpose of the Study:

  • To summarize current knowledge on hyperglycemic control strategies for patients undergoing cardiac surgery.
  • To highlight the importance of perioperative glycemic management in preventing complications.
  • To provide an overview of evidence-based approaches for blood sugar control in this high-risk population.

Main Methods:

  • Review of observational and experimental studies on glycemic control in cardiac surgery patients.
  • Synthesis of current knowledge regarding perioperative hyperglycemia management.
  • Focus on strategies to prevent postoperative complications.

Main Results:

  • Inadequate glycemic control significantly increases the risk of postoperative mortality.
  • Hyperglycemia is linked to serious complications including surgical site infections, sepsis, renal failure, and cardiovascular events.
  • Adequate perioperative glycemic control is the most effective method for preventing these adverse outcomes.

Conclusions:

  • Perioperative glycemic control is paramount for improving outcomes in diabetic patients undergoing cardiac surgery.
  • Implementing effective blood sugar management strategies can mitigate significant risks and complications.
  • This review consolidates current understanding to guide clinical practice in managing hyperglycemia during the perioperative period.

Keywords:
cardiac surgerydiabetesglycemiainsulin therapyperioperative medicine

More Related Videos

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

1.2K
Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

9.4K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
134
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
109
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
204
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
121
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
106